Prioritization schema for immunotherapy clinical trials in glioblastoma

Tiffany R. Hodges, Sherise D. Ferguson, Hillary G. Caruso, Gary Kohanbash, Shouhao Zhou, Timothy F. Cloughesy, Mitchel S. Berger, George Poste, Mustafa Khasraw, Sujuan Ba, Tao Jiang, Tom Mikkelson, W. K Alfred Yung, John F. de Groot, Howard Fine, Lewis C. Cantley, Ingo K. Mellinghoff, Duane A. Mitchell, Hideho Okada, Amy B. Heimberger

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials. Methods: The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of these categories is subdivided to focus on the most salient elements for developing a successful immunotherapeutic approach for GBM, and a numerical score is generated. Results: The Score Card reveals therapeutics that have the most robust data to support their use, provides a reference prioritization score, and can be applied in a reiterative fashion with emerging data. Conclusions: The authors hope that this schema will give physicians an evidence-based and rational framework to make the best referral decisions to better guide and serve this patient population.

Original languageEnglish (US)
JournalOncoImmunology
DOIs
StateAccepted/In press - May 16 2016

Fingerprint

Glioblastoma
Immunotherapy
Clinical Trials
Hope
Therapeutics
Subunit Vaccines
Heat-Shock Proteins
Dendritic Cells
Names
Referral and Consultation
Vaccines
Physicians
T-Lymphocytes
Population

Keywords

  • Clinical trial
  • glioblastoma
  • immunotherapy
  • prioritization
  • score card

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Hodges, T. R., Ferguson, S. D., Caruso, H. G., Kohanbash, G., Zhou, S., Cloughesy, T. F., ... Heimberger, A. B. (Accepted/In press). Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology. https://doi.org/10.1080/2162402X.2016.1145332

Prioritization schema for immunotherapy clinical trials in glioblastoma. / Hodges, Tiffany R.; Ferguson, Sherise D.; Caruso, Hillary G.; Kohanbash, Gary; Zhou, Shouhao; Cloughesy, Timothy F.; Berger, Mitchel S.; Poste, George; Khasraw, Mustafa; Ba, Sujuan; Jiang, Tao; Mikkelson, Tom; Yung, W. K Alfred; de Groot, John F.; Fine, Howard; Cantley, Lewis C.; Mellinghoff, Ingo K.; Mitchell, Duane A.; Okada, Hideho; Heimberger, Amy B.

In: OncoImmunology, 16.05.2016.

Research output: Contribution to journalArticle

Hodges, TR, Ferguson, SD, Caruso, HG, Kohanbash, G, Zhou, S, Cloughesy, TF, Berger, MS, Poste, G, Khasraw, M, Ba, S, Jiang, T, Mikkelson, T, Yung, WKA, de Groot, JF, Fine, H, Cantley, LC, Mellinghoff, IK, Mitchell, DA, Okada, H & Heimberger, AB 2016, 'Prioritization schema for immunotherapy clinical trials in glioblastoma', OncoImmunology. https://doi.org/10.1080/2162402X.2016.1145332
Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF et al. Prioritization schema for immunotherapy clinical trials in glioblastoma. OncoImmunology. 2016 May 16. https://doi.org/10.1080/2162402X.2016.1145332
Hodges, Tiffany R. ; Ferguson, Sherise D. ; Caruso, Hillary G. ; Kohanbash, Gary ; Zhou, Shouhao ; Cloughesy, Timothy F. ; Berger, Mitchel S. ; Poste, George ; Khasraw, Mustafa ; Ba, Sujuan ; Jiang, Tao ; Mikkelson, Tom ; Yung, W. K Alfred ; de Groot, John F. ; Fine, Howard ; Cantley, Lewis C. ; Mellinghoff, Ingo K. ; Mitchell, Duane A. ; Okada, Hideho ; Heimberger, Amy B. / Prioritization schema for immunotherapy clinical trials in glioblastoma. In: OncoImmunology. 2016.
@article{e153de446b214380a86818a85b044cd2,
title = "Prioritization schema for immunotherapy clinical trials in glioblastoma",
abstract = "Background: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials. Methods: The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of these categories is subdivided to focus on the most salient elements for developing a successful immunotherapeutic approach for GBM, and a numerical score is generated. Results: The Score Card reveals therapeutics that have the most robust data to support their use, provides a reference prioritization score, and can be applied in a reiterative fashion with emerging data. Conclusions: The authors hope that this schema will give physicians an evidence-based and rational framework to make the best referral decisions to better guide and serve this patient population.",
keywords = "Clinical trial, glioblastoma, immunotherapy, prioritization, score card",
author = "Hodges, {Tiffany R.} and Ferguson, {Sherise D.} and Caruso, {Hillary G.} and Gary Kohanbash and Shouhao Zhou and Cloughesy, {Timothy F.} and Berger, {Mitchel S.} and George Poste and Mustafa Khasraw and Sujuan Ba and Tao Jiang and Tom Mikkelson and Yung, {W. K Alfred} and {de Groot}, {John F.} and Howard Fine and Cantley, {Lewis C.} and Mellinghoff, {Ingo K.} and Mitchell, {Duane A.} and Hideho Okada and Heimberger, {Amy B.}",
year = "2016",
month = "5",
day = "16",
doi = "10.1080/2162402X.2016.1145332",
language = "English (US)",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",

}

TY - JOUR

T1 - Prioritization schema for immunotherapy clinical trials in glioblastoma

AU - Hodges, Tiffany R.

AU - Ferguson, Sherise D.

AU - Caruso, Hillary G.

AU - Kohanbash, Gary

AU - Zhou, Shouhao

AU - Cloughesy, Timothy F.

AU - Berger, Mitchel S.

AU - Poste, George

AU - Khasraw, Mustafa

AU - Ba, Sujuan

AU - Jiang, Tao

AU - Mikkelson, Tom

AU - Yung, W. K Alfred

AU - de Groot, John F.

AU - Fine, Howard

AU - Cantley, Lewis C.

AU - Mellinghoff, Ingo K.

AU - Mitchell, Duane A.

AU - Okada, Hideho

AU - Heimberger, Amy B.

PY - 2016/5/16

Y1 - 2016/5/16

N2 - Background: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials. Methods: The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of these categories is subdivided to focus on the most salient elements for developing a successful immunotherapeutic approach for GBM, and a numerical score is generated. Results: The Score Card reveals therapeutics that have the most robust data to support their use, provides a reference prioritization score, and can be applied in a reiterative fashion with emerging data. Conclusions: The authors hope that this schema will give physicians an evidence-based and rational framework to make the best referral decisions to better guide and serve this patient population.

AB - Background: Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials. Methods: The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of these categories is subdivided to focus on the most salient elements for developing a successful immunotherapeutic approach for GBM, and a numerical score is generated. Results: The Score Card reveals therapeutics that have the most robust data to support their use, provides a reference prioritization score, and can be applied in a reiterative fashion with emerging data. Conclusions: The authors hope that this schema will give physicians an evidence-based and rational framework to make the best referral decisions to better guide and serve this patient population.

KW - Clinical trial

KW - glioblastoma

KW - immunotherapy

KW - prioritization

KW - score card

UR - http://www.scopus.com/inward/record.url?scp=84969610644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969610644&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2016.1145332

DO - 10.1080/2162402X.2016.1145332

M3 - Article

AN - SCOPUS:84969610644

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

ER -